CN1452482A - 含有胆碱和琥珀酸用于治疗胰岛素抵抗和糖尿病的协同组成物 - Google Patents

含有胆碱和琥珀酸用于治疗胰岛素抵抗和糖尿病的协同组成物 Download PDF

Info

Publication number
CN1452482A
CN1452482A CN00819413A CN00819413A CN1452482A CN 1452482 A CN1452482 A CN 1452482A CN 00819413 A CN00819413 A CN 00819413A CN 00819413 A CN00819413 A CN 00819413A CN 1452482 A CN1452482 A CN 1452482A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
succinic acid
choline
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00819413A
Other languages
English (en)
Chinese (zh)
Inventor
帕密特金·伊戈尔·阿那托列维奇
卡列索瓦·奥尔加·伊夫吉涅芙娜
马卡诺娃·塔奇亚娜·裘列娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1452482A publication Critical patent/CN1452482A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN00819413A 2000-04-10 2000-04-10 含有胆碱和琥珀酸用于治疗胰岛素抵抗和糖尿病的协同组成物 Pending CN1452482A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2000/000122 WO2001076583A1 (en) 2000-04-10 2000-04-10 Synergistic compositions containing choline base and succinic acid for insulin resistance and diabetes

Publications (1)

Publication Number Publication Date
CN1452482A true CN1452482A (zh) 2003-10-29

Family

ID=20129496

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00819413A Pending CN1452482A (zh) 2000-04-10 2000-04-10 含有胆碱和琥珀酸用于治疗胰岛素抵抗和糖尿病的协同组成物

Country Status (8)

Country Link
EP (1) EP1272171A1 (enExample)
JP (1) JP3944393B2 (enExample)
KR (1) KR20020089444A (enExample)
CN (1) CN1452482A (enExample)
AU (1) AU2000263274A1 (enExample)
BR (1) BR0017206A (enExample)
CA (1) CA2404864A1 (enExample)
WO (1) WO2001076583A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102223883B (zh) * 2008-11-26 2013-07-10 伊戈尔·安那托利维奇·波米特金 用于治疗抑郁症、焦虑症、精神分裂症、睡眠障碍和癫痫症的琥珀酸的胆碱盐
CN107456449A (zh) * 2016-12-09 2017-12-12 杨远志 一种组合物及其在增加肌肉耐力中的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112773A1 (en) * 2003-04-24 2004-12-29 Shin-Jen Shiao Pharmaceutical compositions used for immune disease treatment and improvement
EA017094B1 (ru) * 2007-08-02 2012-09-28 Игорь Анатольевич Помыткин Фармацевтические композиции, содержащие холиновые соли янтарной кислоты, для интраназального введения
US8314080B2 (en) 2010-04-06 2012-11-20 Kuwait University Method of treating type I diabetes
GB202112170D0 (en) * 2021-08-25 2021-10-06 Mitocholine Ltd Nutritional compositions
WO2024231663A1 (en) 2023-05-05 2024-11-14 Mitocholine Ltd Method of synthesis
WO2025163212A2 (en) 2024-08-09 2025-08-07 Jantar Gmbh Succinic acid or a pharmaceutically acceptable salt thereof for use in the treatment of chronic rhinosinusitis
WO2025120626A2 (en) 2025-04-14 2025-06-12 Mitocholine Ltd Synthetic method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6346669D0 (pt) * 1962-02-12 1973-06-14 Squibb & Sons Inc Processo de preparacao de uma composicao farmaceutica estavel de sais de esteres de colina
JPS61171417A (ja) * 1985-01-23 1986-08-02 Wakunaga Seiyaku Kk 抗糖尿病剤
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
JPH03169498A (ja) * 1989-11-28 1991-07-23 Yotsukaichi Gosei Kk 水溶性はんだフラックス
JPH0586319A (ja) * 1991-09-27 1993-04-06 Pentel Kk 水性インキ組成物
US5895652A (en) * 1996-07-29 1999-04-20 Longevity Institute International Method of metabolic adjuvanation and cellular repair
ES2222717T3 (es) * 1999-03-01 2005-02-01 Verteletsky, Pavel Vasilievich Uso de acido succinico o sus sales y metodo de tratamiento de la resistencia a la insulina.
WO2000059499A1 (en) * 1999-04-05 2000-10-12 Verteletsky, Pavel Vasilievich Use of succinic acid or salts thereof for the treatment of diabetes mellitus and wound healing

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102223883B (zh) * 2008-11-26 2013-07-10 伊戈尔·安那托利维奇·波米特金 用于治疗抑郁症、焦虑症、精神分裂症、睡眠障碍和癫痫症的琥珀酸的胆碱盐
CN107456449A (zh) * 2016-12-09 2017-12-12 杨远志 一种组合物及其在增加肌肉耐力中的应用

Also Published As

Publication number Publication date
KR20020089444A (ko) 2002-11-29
JP3944393B2 (ja) 2007-07-11
AU2000263274A1 (en) 2001-10-23
JP2004506605A (ja) 2004-03-04
EP1272171A1 (en) 2003-01-08
WO2001076583A1 (en) 2001-10-18
CA2404864A1 (en) 2001-10-18
BR0017206A (pt) 2003-01-14

Similar Documents

Publication Publication Date Title
CN1138539C (zh) 用于降低神经酰胺水平的碱性氨基酸和衍生物的应用
JP2012515801A (ja) 糖尿病及び肥満症を治療するためのプテロシン化合物の使用
JP3944393B2 (ja) インスリン抵抗性および糖尿病のための、コリン塩基とコハク酸とを含む相乗効果のある組成物
EP2992888B1 (en) Use of pentacyclic triterpenoid saponin compound from szechuan melandium root for preparing hypoglycemic drug
EP1014808B1 (en) Fatty acids as a diet supplement
CN1777417B (zh) PPARα激动剂和二甲双胍降低血清甘油三酯的用途
EP4331583A1 (en) Blood carnitine-increasing agent
CN1703244A (zh) Ppar配体和抗氧剂间的联合及其用于治疗肥胖的用途
US6521665B1 (en) Method of treating insulin resistance
CA3104916C (en) Pharmaceutical composition for preventing diabetes and use thereof
CN1358092A (zh) 含有西布曲明和奥利司他的药物组合物
WO2002012177A1 (en) Composition of metformin with succinic acid or salts thereof and method for treating diabetes
WO2002096410A1 (en) Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
CN1823787A (zh) 灵芝酸在制备癌转移抑制剂中的应用
KR20210015883A (ko) 당뇨 제어 및 염증성장질환 치료의 향상을 위한 구조적으로 변형된 지방산
WO2023163992A1 (en) Modulation of human breast milk composition
JPH04198134A (ja) 老人性痴呆症の治療・予防剤
CN1232255C (zh) 糖尿病治疗剂
CN1976696A (zh) 用于预防或治疗脂质代谢异常的医药组合物
WO2026007239A1 (zh) 灵芝酸a在制备预防和/或治疗非酒精性脂肪肝病的产品中的应用
CN121648090A (zh) 一种内源性代谢物小分子ggoh在制备肝癌药物中的应用
CN102743370B (zh) 双醋瑞因的用途
WO2008038712A1 (fr) Agent thérapeutique/prophylactique du syndrome métabolique
JP2023505233A5 (enExample)
CN1741798A (zh) 预防或治疗子宫内生长迟缓和妊娠毒血症的药物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication